Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Subscribe To Our Newsletter & Stay Updated
